Methodological analysis questions predictive value of plasma p-tau217 disease clocks for Alzheimer's onset
This methodological analysis examined whether reported predictive performance of plasma %p-tau217 disease clocks for symptomatic Alzheimer's disease onset reflects genuine biomarker information or structural artifacts. The study analyzed digitized data from published figures of ADNI participants who progressed during follow-up, comparing disease clock models (SILA and TIRA) against baseline age alone and randomized predictors that replaced the biomarker-derived timing component.
Baseline age alone explained 78% of variance (R²=0.78) in predicting age at symptom onset. The TIRA clock-derived predictor explained 33.7% of variance (R²=0.337), while the SILA clock-derived predictor explained 47.0% (R²=0.470). Randomized predictors that replaced the biomarker timing component performed similarly to baseline age (R²=0.79), suggesting the estimated time from %p-tau217 positivity contributed minimal additional information beyond structural age relationships.
Safety and tolerability data were not reported. Key limitations include the analysis of digitized data rather than original datasets, unspecified sample size, and limited follow-up duration. The study suggests reported predictive performance of plasma %p-tau217 disease clocks appears driven by structural artifacts rather than independent biomarker signal, with the combination of biomarker timing with age obscuring structural dependencies. Practice relevance remains uncertain given the methodological nature of this analysis.